ViAqua Therapeutics
Oral Delivery Platform for Preventing Aquaculture Diseases
Company Overview
Snapshot
Founded in September 2014 by Shai Ufaz and Shai Einbinder, ViAqua Therapeutics operates with 11–50 employees. The company has raised a total of $16.05 million across 5 funding rounds from 11 investors. In September 2023, the company secured funding from investors including S2G Investments.
Business overview
ViAqua Therapeutics develops an orally administered treatment platform aimed at improving health management and preventing viral epidemics in aquaculture. The company's core technology utilizes a proprietary RNAi formulation delivered via coated particles in feed, which triggers the immune system to prevent viral infections in shellfish and fish. Its initial product targets shrimp, a significant segment of the international fish products trade, operating within the Agriculture & Food Technologies sector and serving markets in Asia, South America, and Australia.
Strategic signal
In September 2023, ViAqua Therapeutics successfully raised $8.25 million in a funding round. This capital infusion, with participation from investors such as S2G Investments and I-Lab Angels, signals continued investor confidence in. The funding supports the company's ongoing development and commercialization efforts, reinforcing its trajectory as a key innovator in sustainable farming and disease management.
Log in to access full profile ›Company Intelligence Q&A
- What is ViAqua Therapeutics' primary focus?
- ViAqua Therapeutics focuses on developing an orally administered treatment platform for preventing viral epidemics and improving health management in aquaculture, particularly for shellfish and fish.
- When was ViAqua Therapeutics founded?
- ViAqua Therapeutics was founded in September 2014.
- Which investors participated in the September 2023 funding round?
- In September 2023, ViAqua Therapeutics received funding from investors including.
- What is the core technology behind ViAqua Therapeutics' products?
- ViAqua Therapeutics utilizes a proprietary RNAi formulation delivered through coated particles via feed, which triggers the immune system to prevent viral infections in aquatic species.
- Which investors participated in the June 2021 funding round?
- In June 2021, ViAqua Therapeutics received investment from S2G Investments and Thai Union Group.